Efectos del ciclamato de sodio en el hígado fetal de ratas estudios cariometico y estreologico

International Journal of Morphology, Sept, 2005 by Alex Tadeu Martins, Reinaldo Azoubel, Ruberval A. Lopes, Miguel A. Sala di Matteo, José Germano Ferraz de Arruda

In agreement with Richards et al. in their study of different methods for administering sodium cyclamate in various animal species, there was no alteration in renal or hepatic functions in the groups studied. However, many of these presented inflammatory lesions and vacuolizations that, according to the author, are associated uniquely with the osmotic effect of edulcorant.

Branton et al. evaluated 60 mice which, divided into groups, received a diet of 0.7, 1.75, 3.5 or 7% sodium cyclamate for 80 weeks. According to these authors, the effect in those red the diet with 7% additive became evident since, among other alterations, all animals in the subgroup presented a reduced number of erythrocytes and a decreased concentration of hemoglobin.

In summary, this work represents a valuable contribution through its original karyometric-stereologic verification in the rat fetus liver, by detecting intense hepatic alterations resulting from intraperitoneal administration of sodium cyclamate. It can be concluded that sodium cyclamate administered intraperitoneally from the 10th to the 14th day of pregnancy causes: 1) diminished fetal weight, placental weight and umbilical-cord length compared to the control group, suggesting retardation of fetal development, and 2) hepatic cellular hypertrophy (cytoplasm and nucleus) with small-caliber sinusoids.

REFERENCES

Ahmed, F. E. & Thomas D. B. Assessment of carcinogenicity of the nonnutritive sweetner cyclamate. Crit. Rev. Toxicol., 22:81-118, 1992.

Assunção, M. C. E" Anderson, G. B. & Cavalcanti, Z. C. H. Uso de adoçantes alternativos pelos diabético. JBM, 67:62-9, 1994.

Audreith, L. E & Sveda, M. Preparation and properties of some N-substituted sulphamic acids. J. Org. Chem., 9:89-101, 1944.

Barlattani, M. Rassegne sintetiche di terapia. Il problema dei ciclamati. Cl. Terap., 52:565-60, 1970.

Boop, B. A.; Sonders, R. C. & Kesterson, J. W. Toxicological aspects of cyclamate and cyclohexylamine. Crit. Rev. Toxicol., 16:213-306, 1986.

Branton, P. G.; Gaunt, I. F. & Grasso. P. Long-term toxicity of sodium cyclamate in mice. Food Cosmet. Toxicol., 11:735, 1973.

Burbank, F. & Fraumeni Jr, J. F. Synthetic sweetener consumption and bladder cancer trends in the United States. Nature, 227:296-7, 1970.

Cattanach, B .M. The mutagenicity of cyclamates and their metabolites. Mutat. Res., 39:1-28, 1976.

Coulston, E; McChesney, E. W. & Golberg, L. Long-term administration of artificial sweeteners to the Rhesus monkey (M. mulatta). Food Cosmet. Toxicol., 13:297, 1975.

Egeberg, R. O.; Steinfeld, J. L.; Frantz, I.; Griffith, G. C.; Knowles Jr, R. H.; Rosenow, E.; Sebrell, H. & Van Itallie T. Report to the secretary of HEW from the Medical Advisory Group on cyclamates. JAMA, 211:1358-61, 1970.

Göttinger, E.; Hagmüller, K.; Hellauer, H. & Vinazzer, H. The effect of cyclamate, a sweetening agent, on liver parenchyma, corresponding enzymes and blood clotting factors. Wein. Klin. Wschr., 80:328, 1968.

Hagmüller, K.; Hellauer, H.; Winkler, R. & Zangger, J. New histological findings and further experimental data on the question of cyclamate tolerance in the guinea pig. Wein. Klin. Wschr., 81:927, 1969.